{"parse":{"title":"Intermittent preventive therapy","pageid":23497821,"revid":766795002,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Intermittent preventive therapy</b> or <b>intermittent preventive treatment</b> (<b>IPT</b>) is a <a href=\"/wiki/Public_health\" title=\"Public health\">public health</a> intervention aimed at treating and preventing <a href=\"/wiki/Malaria\" title=\"Malaria\">malaria</a> episodes in infants (IPTi), children (IPTc), schoolchildren (IPTsc) and pregnant women (IPTp). The intervention builds on two tested malaria control strategies to clear existing parasites (treatment effect seen in <a href=\"/wiki/Mass_drug_administration\" title=\"Mass drug administration\">mass drug administrations</a>) and to prevent new infections (<a href=\"/wiki/Prophylaxis\" class=\"mw-redirect\" title=\"Prophylaxis\">prophylaxis</a>).\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#IPTi\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">IPTi</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#IPTc\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">IPTc</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#IPTsc\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">IPTsc</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#IPTp\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">IPTp</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Controversy\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Controversy</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Politics\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Politics</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#External_links\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"IPTi\">IPTi</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=1\" title=\"Edit section: IPTi\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>IPTi using the antimalarial drug <a href=\"/wiki/Sulfadoxine\" title=\"Sulfadoxine\">sulfadoxine</a>/<a href=\"/wiki/Pyrimethamine\" title=\"Pyrimethamine\">pyrimethamine</a> (S/P) was pioneered in Ifakara, Tanzania in 1999.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> Infants received S/P at ages 3, 6, and 9 months in combination with their routine childhood (EPI) vaccinations. IPTi reduced clinical attacks of malaria by 59% (95% CI, 41%\u201372%) in Ifakara. Remarkably, protection persisted throughout the second year of life, long after SP had disappeared from circulation.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup> A trial conducted in northern Tanzania using the antimalarial drug amodiaquine instead of S/P was similarly successful.<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> Six subsequent trials showed less encouraging results.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup>\n</p><p>The latest and so far largest IPTi study was an effectiveness study conducted in the South East of Tanzania.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup> A study area of approximately 250x180km2 with a population of about 900,000 people was subdivided into 24 similar clusters. Half of the 23,400 infants, those residing in 12 of 24 randomly selected clusters were invited in 2005 to receive IPTi. Between 47 and 76% of the eligible infants in each of the 12 selected clusters received IPT-SP. In the following year, 2006, the effect of IPTi on malaria and anaemia was assessed in a representative sample of 600 infants. An intention to treat analysis, which includes all eligible infants did not show a statistically significant benefit of IPTi-SP. Parasitaemia prevalence was 31% in the intervention and 38% in the comparison areas (p=0.06). In a \u2018per protocol\u2019 analysis, which only included infants who actually received IPTi there was a significant benefit: parasite prevalence was 22%, 19 percentage points lower than comparison children in the control group (p=0.01). This trial showed that IPTi has a protective effect at the individual level but is not effective at the community level. The study had followed up children for two years until 2007 but the findings from the surveillance in 2007 have not been reported.\n</p>\n<h2><span class=\"mw-headline\" id=\"IPTc\">IPTc</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=2\" title=\"Edit section: IPTc\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Treating children with S/P and artesunate in Senegal where malaria is highly seasonal repeatedly during the malaria season reduced malaria attacks by 86% (95% CI 80-90)9.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup> A subsequent trial in Mali showed a protective efficacy of 43% [95% CI 29%-54%].<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"IPTsc\">IPTsc</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=3\" title=\"Edit section: IPTsc\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Treating schoolchildren in Kenya with S/P and <a href=\"/wiki/Amodiaquine\" title=\"Amodiaquine\">amodiaquine</a> significantly improved anaemia (RR 0.52, 95% CI 0.29-0.93).<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"IPTp\">IPTp</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=4\" title=\"Edit section: IPTp\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>IPTp consists in the administration of a single curative dose of an efficacious anti-malarial drug at least twice during pregnancy \u2013 regardless whether or not the woman is infected. The drug is administered under supervision during antenatal care (ANC) visits. Sulfadoxine-pyrimethamine is the drug currently recommended by the WHO because of its safety and efficacy in pregnancy.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> Several studies have shown the high efficacy of IPTp with SP, compared to placebo or CQ prophylaxis, on placental infection, LBW and/or severe maternal anaemia.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> More recent findings from Tanzania also suggest that IPTp using S/P has reached the end of its lifecycle.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> The authors found that the \"use of partially effective anti-malarial agents for IPTp may exacerbate malaria infections in the setting of widespread drug resistance\". As for infants, there is no simple readily available replacement of S/P for malaria in pregnancy. Indeed, the fear of teratogenic effects add a layer of complexity how this intervention will evolve.\n</p>\n<h2><span class=\"mw-headline\" id=\"Controversy\">Controversy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=5\" title=\"Edit section: Controversy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>While some controversial aspects e.g. the drug of choice are shared by all forms of intermittent preventive therapy, the controversy has been reported in greatest detail for IPTi (see also politics below). The reasons which make the large scale introduction of IPTi highly controversial include:<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p>\n<ol><li>The six studies reported subsequent to the first 2 IPTi studies did not confirm the same degree of protection against malaria (59%) nor the protracted period of protective benefit (into the second year of life) seen in that initial study. Subsequent studies indicated that protection lasted about 35 days after each treatment dose, which translates into an overall protective efficacy in infancy of 20\u201333%.</li>\n<li>Effects on anaemia and hospital admission were inconsistent between study sites.</li>\n<li>There was no evidence of mortality reduction. In more than 8,000 children enrolled in IPTi studies, there were 152 deaths in the placebo groups and 157 deaths in the sulfadoxine-pyrimethamine groups: a protective efficacy of \u20132% (95% CI \u201322 to 21).</li>\n<li>There were concerns that any benefits shown in these IPTi-SP trials might be less now that resistance to sulfadoxine-pyrimethamine has worsened. A recent trial of S/P conducted in Tanzania had to be closed early because of high mortality in children receiving S/P.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup></li>\n<li>There was uncertainty over the true incidence of serious adverse effects, notably the cutaneous reactions that stopped the use of sulfadoxine pyrimethamine as prophylaxis.</li></ol>\n<p>An added theoretical concern is that the widespread use of antimalarial drugs for prophylaxis will add to the already considerable drug pressure and will facilitate the emergence and spread of drug resistance. McGready summarised IPTi as an intervention which uses the wrong drug, probably in the wrong dose in the wrong age group.<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Politics\">Politics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=6\" title=\"Edit section: Politics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The politics of IPTi are well documented and illustrate the working of contemporary international health politics. The promising results of the first two IPTi studies led to the creation of the IPTi Consortium, whose brief is to determine the efficacy, safety, relation of efficacy to drug sensitivity, cost-effectiveness, and acceptability of this intervention.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> The IPTi Consortium received approximately US$28 million from the <a href=\"/wiki/Bill_%26_Melinda_Gates_Foundation\" title=\"Bill &amp; Melinda Gates Foundation\">Bill &amp; Melinda Gates Foundation</a> (BMGF). A <a href=\"/wiki/WHO\" class=\"mw-redirect\" title=\"WHO\">WHO</a> technical advisory group reviewed the evidence relevant for the widespread  introduction of IPTi  available in 2008, and came to the conclusion that the available evidence was not sufficient to recommend the widespread introduction of IPTi -SP. Program officers of the BMGF as well as scientists funded by the BMGF criticised the WHO conclusions. The criticism from the BMGF in turn triggered a memorandum of the WHO malaria chief Dr. Akira Kochi to the director general of the WHO which was leaked to <i>The New York Times</i>.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup>\n</p>\n<style data-mw-deduplicate=\"TemplateStyles:r856303468\">.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}</style><blockquote class=\"templatequote\"><p>Dr. Kochi wrote, although it was less and less straightforward  that the health agency should recommend IPTi, the agency's objections were met with intense and aggressive opposition from Gates-backed scientists and the foundation. The W.H.O., he wrote, needs to stand up to such pressures and ensure that the review of evidence is rigorously independent of vested interests.\n</p></blockquote>\n<p>At the request of Dr. Brandling-Bennett of the BMGF and with funding from the BMGF, the <a href=\"/wiki/Institute_of_Medicine\" class=\"mw-redirect\" title=\"Institute of Medicine\">Institute of Medicine</a> (IOM) convened an expert committee to evaluate the evidence concerning IPTi - SP and provide guidance on the value of continued investment in IPTi-SP. The committee was chaired by Myron M. Levine who has been funded and is currently funded by the BMGF. The committee concluded \"\u2026 that an intervention with results of this magnitude is worthy of further investment as part of a public health strategy to decrease morbidity from malaria infections in infants.\"<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> The WHO technical expert group responded to the IOM report \"WHO is committed to review the available information each year.\" Dr. Kochi was ultimately replaced by one of the members of the IPTi consortium, Dr. Robert Newman. In March 2010, i.e. after Dr. Kochi had been replaced, the WHO recommended the co-administration of the antimalarial drug sulfadoxine pyrimethamine with routine childhood vaccinations (<a href=\"/wiki/DPT_vaccine\" title=\"DPT vaccine\">DTP2, DTP3</a> and measles immunization) in sub-Saharan Africa.<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup> The recommendation applies only for areas with high malaria transmission and low resistance against SP, both measures are not free of controversy and only available for few spots in Africa. With the recent drop of malaria transmission in wide stretches of Africa<sup id=\"cite_ref-30\" class=\"reference\"><a href=\"#cite_note-30\">&#91;30&#93;</a></sup><sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup> and a steady increase in SP resistance<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup><sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup> few malaria control programs will hurry to implement this intervention.\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=7\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\">Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001;357(9267):1471-7</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\">Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005;365(9469):1481-3</span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\">Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, et al. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet 2003;361(9372):1853-60</span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\">Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, et al. <a href=\"/wiki/Cluster_randomised_trial\" class=\"mw-redirect\" title=\"Cluster randomised trial\">Cluster randomised trial</a> of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 2005;331(7519):727-33</span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis 2006;194(3):276-85</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\">Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, Potschke M, et al. Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis 2007;196(11):1595-602</span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\">Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson PA, et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 2007;45(1):16-25</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\">Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 2007;51(9):3273-81</span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\">Armstrong Schellenberg, J.R., et al., Community effectiveness of Intermittent Preventive Treatment for infants (IPTi) in rural southern Tanzania. Am J Trop Med Hyg, 2010. 82(5): p. 772-81.</span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\">.Cisse B, Sokhna C, Boulanger D, Milet J, Ba el H, Richardson K, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006;367(9511):659-67</span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\">Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 2008;7:123</span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\">Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundill B, Otido J, et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9633):127-38</span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\">WHO. A strategic framework for malaria prevention and control during pregnancy in the Africa Region.  Geneva: WorldHealthOrganization, 2004 AFR/MAL/04/01</span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\">Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999;353(9153):632-6</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\">Challis K, Osman NB, Cotiro M, Nordahl G, Dgedge M, Bergstrom S. Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique. Trop Med Int Health 2004;9(10):1066-73</span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\">Kayentao K, Kodio M, Newman RD, Maiga H, Doumtabe D, Ongoiba A, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis 2005;191(1):109-16</span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\">Njagi JK, Magnussen P, Estambale B, Ouma J, Mugo B. Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: a randomized controlled trial. Trans R Soc Trop Med Hyg 2003;97(3):277-82</span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\">Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998;59(5):813-22</span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\">Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME. Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-99. Trans R Soc Trop Med Hyg 2000;94(5):549-53</span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\">van Eijk AM, Ayisi JG, ter Kuile FO, Otieno JA, Misore AO, Odondi JO, et al. Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. Trop Med Int Health 2004;9(3):351-60</span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\">Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birth weight in rural Malawi. Ann Trop Med Parasitol 1998;92(2):141-50</span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\">Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A 2009;106(22):9027-32</span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\">Intermittent preventive antimalarial treatment in infancy. Lancet 2008;372(9647):1383-4</span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\">:Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. <a href=\"/wiki/PLoS_ONE\" class=\"mw-redirect\" title=\"PLoS ONE\">PLoS ONE</a> 2009;4(2):e4569</span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\">McGready, R., Intermittent preventive treatment of malaria in infancy. Lancet, 2009. 9700(374): p. 1478-80.</span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\">.Schellenberg D, Cisse B, Menendez C. The IPTi Consortium: research for policy and action. Trends Parasitol 2006;22(7):296-300</span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\">New York Times, February 16, 2008 Gates Foundation's Influence Criticized  By DONALD G. McNEIL Jr.</span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\">Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants. Assessment of the role of intermittent preventive treatment for malaria in infants: letter report. Washington, DC:Institute f Medicine, 2008. <a rel=\"nofollow\" class=\"external free\" href=\"http://www.nap.edu/catalog.php?record_id=12180\">http://www.nap.edu/catalog.php?record_id=12180</a></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.who.int/malaria/news/policy_recommendation_IPTi_032010/en/index.html\">https://www.who.int/malaria/news/policy_recommendation_IPTi_032010/en/index.html</a></span>\n</li>\n<li id=\"cite_note-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-30\">^</a></b></span> <span class=\"reference-text\">O'Meara, W.P., et al., Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet, 2008. 372(9649): p. 1555-62. 3.</span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\">Ceesay, S.J., et al., Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet, 2008. 372(9649): p. 1545-54</span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\">Gesase, S., et al., High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. <a href=\"/wiki/PLoS_ONE\" class=\"mw-redirect\" title=\"PLoS ONE\">PLoS ONE</a>, 2009. 4(2): p. e4569.</span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\">Raman, J., et al., Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg, 2010. 82(5): p. 788-94.</span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Intermittent_preventive_therapy&amp;action=edit&amp;section=8\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<table role=\"presentation\" class=\"mbox-small plainlinks sistersitebox\" style=\"background-color:#f9f9f9;border:1px solid #aaa;color:#000\">\n<tbody><tr>\n<td class=\"mbox-image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/fa/Wikiquote-logo.svg/34px-Wikiquote-logo.svg.png\" width=\"34\" height=\"40\" class=\"noviewer\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/fa/Wikiquote-logo.svg/51px-Wikiquote-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fa/Wikiquote-logo.svg/68px-Wikiquote-logo.svg.png 2x\" data-file-width=\"300\" data-file-height=\"355\" /></td>\n<td class=\"mbox-text plainlist\">Wikiquote has quotations related to: <i><b><a href=\"https://en.wikiquote.org/wiki/Special:Search/Intermittent_preventive_therapy\" class=\"extiw\" title=\"q:Special:Search/Intermittent preventive therapy\">Intermittent preventive therapy</a></b></i></td></tr></tbody></table>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ipti-malaria.org/\"><i>IPTi consortium </i></a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2008/02/16/science/16malaria.html?_r=1&amp;scp=1&amp;sq=Gates%20Foundation%E2%80%99s%20Influence%20Criticized%20&amp;st=cse\"><i>New York Times 2/16/08</i></a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nap.edu/catalog.php?record_id=12180\"><i>IoM report on IPTi</i></a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1268\nCached time: 20180901201258\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.112 seconds\nReal time usage: 0.137 seconds\nPreprocessor visited node count: 525/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 3105/2097152 bytes\nTemplate argument size: 641/2097152 bytes\nHighest expansion depth: 8/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 15115/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.006/10.000 seconds\nLua memory usage: 616 KB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   72.900      1 -total\n 62.70%   45.710      1 Template:Reflist\n 16.09%   11.731      1 Template:Wikiquote\n 15.84%   11.546      1 Template:Quote\n 13.19%    9.617      1 Template:Sister_project\n  9.46%    6.899      1 Template:Side_box\n  2.79%    2.031      1 Template:Main_other\n  2.60%    1.896      1 Template:Column-width\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:23497821-0!canonical and timestamp 20180901201258 and revision id 766795002\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D8%B9%D9%84%D8%A7%D8%AC_%D9%88%D9%82%D8%A7%D8%A6%D9%8A_%D9%85%D8%AA%D9%82%D8%B7%D8%B9","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0639\u0644\u0627\u062c \u0648\u0642\u0627\u0626\u064a \u0645\u062a\u0642\u0637\u0639"}],"categories":[{"sortkey":"Intermittent Preventive Therapy","*":"Epidemiology"},{"sortkey":"Intermittent Preventive Therapy","*":"Malaria"},{"sortkey":"Intermittent Preventive Therapy","*":"Tropical_diseases"},{"sortkey":"Intermittent Preventive Therapy","*":"Public_health_education"}],"links":[{"ns":0,"exists":"","*":"Amodiaquine"},{"ns":0,"exists":"","*":"Bill & Melinda Gates Foundation"},{"ns":0,"exists":"","*":"Cluster randomised trial"},{"ns":0,"exists":"","*":"DPT vaccine"},{"ns":0,"exists":"","*":"Institute of Medicine"},{"ns":0,"exists":"","*":"Malaria"},{"ns":0,"exists":"","*":"Mass drug administration"},{"ns":0,"exists":"","*":"PLoS ONE"},{"ns":0,"exists":"","*":"Prophylaxis"},{"ns":0,"exists":"","*":"Public health"},{"ns":0,"exists":"","*":"Pyrimethamine"},{"ns":0,"exists":"","*":"Sulfadoxine"},{"ns":0,"exists":"","*":"WHO"}],"templates":[{"ns":10,"exists":"","*":"Template:Quote"},{"ns":10,"exists":"","*":"Template:Quote/styles.css"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Wikiquote"},{"ns":10,"exists":"","*":"Template:Sister project"},{"ns":10,"exists":"","*":"Template:Side box"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Side box"},{"ns":828,"exists":"","*":"Module:Yesno"}],"images":["Wikiquote-logo.svg"],"externallinks":["http://www.nap.edu/catalog.php?record_id=12180","https://www.who.int/malaria/news/policy_recommendation_IPTi_032010/en/index.html","http://www.ipti-malaria.org/","https://www.nytimes.com/2008/02/16/science/16malaria.html?_r=1&scp=1&sq=Gates%20Foundation%E2%80%99s%20Influence%20Criticized%20&st=cse"],"sections":[{"toclevel":1,"level":"2","line":"IPTi","number":"1","index":"1","fromtitle":"Intermittent_preventive_therapy","byteoffset":469,"anchor":"IPTi"},{"toclevel":1,"level":"2","line":"IPTc","number":"2","index":"2","fromtitle":"Intermittent_preventive_therapy","byteoffset":4612,"anchor":"IPTc"},{"toclevel":1,"level":"2","line":"IPTsc","number":"3","index":"3","fromtitle":"Intermittent_preventive_therapy","byteoffset":5442,"anchor":"IPTsc"},{"toclevel":1,"level":"2","line":"IPTp","number":"4","index":"4","fromtitle":"Intermittent_preventive_therapy","byteoffset":5846,"anchor":"IPTp"},{"toclevel":1,"level":"2","line":"Controversy","number":"5","index":"5","fromtitle":"Intermittent_preventive_therapy","byteoffset":9415,"anchor":"Controversy"},{"toclevel":1,"level":"2","line":"Politics","number":"6","index":"6","fromtitle":"Intermittent_preventive_therapy","byteoffset":11721,"anchor":"Politics"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"7","fromtitle":"Intermittent_preventive_therapy","byteoffset":15998,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"8","index":"8","fromtitle":"Intermittent_preventive_therapy","byteoffset":16031,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Intermittent preventive therapy","iwlinks":[{"prefix":"q","url":"https://en.wikiquote.org/wiki/Special:Search/Intermittent_preventive_therapy","*":"q:Special:Search/Intermittent preventive therapy"}],"properties":[{"name":"defaultsort","*":"Intermittent Preventive Therapy"},{"name":"wikibase_item","*":"Q6047519"}]}}